Drug intelligence / Profile preview

galantamine + trospium

Development stage
Unknown
Modality
Small Molecules
Administration
Oral
01

Overview

Galantamine + trospium is a combination of two small molecule drugs used together primarily in elderly patients who have both Alzheimer's disease (AD) and urge urinary incontinence (UUI). Galantamine is a reversible, competitive inhibitor of acetylcholinesterase, increasing acetylcholine levels and also acting as an allosteric modulator of nicotinic cholinergic receptors. It is approved for the treatment of mild to moderate dementia associated with Alzheimer's disease. Trospium is an antimuscarinic agent that relaxes bladder smooth muscle by antagonizing muscarinic acetylcholine receptors, thereby reducing symptoms of overactive bladder such as urgency and urge incontinence. The combination has been studied for its effects on cognition and urinary symptoms in elderly patients with both AD and UUI; evidence suggests it can be recommended for management of these coexisting conditions[1][2][3][4].

02

Targets

mAChR (Muscarinic acetylcholine receptors)Nicotinic Acetylcholine ReceptorAcetylcholinesterase

Beyond the preview

Go deeper on galantamine + trospium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on galantamine + trospium.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call